TerminatedPhase 2NCT01601626
Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
Studying Primary genito-urinary tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Principal Investigator
- Constance A Benson, MD, M.DUniversity of California, San Diego
- Intervention
- Standard-dose Lopinavir/Ritonavir(drug)
- Enrollment
- 71 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2017
Study locations (9)
- Hospital Nossa Senhora da Conceicao CRS (12201), Porto Alegre, Rio Grande do Sul, Brazil
- Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil
- Les Centres GHESKIO CRS (30022), Port-au-Prince, Haiti
- GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS (31730), Port-au-Prince, Haiti
- Moi University Clinical Research Center CRS (12601), Eldoret, Kenya
- Investigaciones Medicas en Salud (INMENSA) (11302), San Isidro, Lima region, Peru
- Asociacion Civil Impacta Salud y Educacion - Miraf CRS (11301), Lima, Peru
- Wits HIV CRS (11101), Johannesburg, Gauteng, South Africa
- Durban Adult HIV CRS (11201), Durban, South Africa
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01601626 on ClinicalTrials.govOther trials for Primary genito-urinary tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05917210Peer-led Implementation of TB-HIV Education and Adherence Counseling in UgandaYale University
- RECRUITINGNCT07312266Questioning the Epidemiology of Asymptomatic TBBarcelona Institute for Global Health
- RECRUITINGNANCT05842161South Africa Smoking Cessation and Engagement in HIV/TB Care CareMassachusetts General Hospital
- RECRUITINGPHASE3NCT05575518A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary TuberculosisStellah Mpagama
- ACTIVE NOT RECRUITINGPHASE4NCT05118490Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis PatientsThe Aurum Institute NPC
- RECRUITINGNANCT05342064Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered ServiceBaylor College of Medicine